165 related articles for article (PubMed ID: 15166920)
1. The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome.
Chuansumrit A; Tangnararatchakit K; Lektakul Y; Pongthanapisith V; Nimjaroenniyom N; Thanarattanakorn P; Wongchanchailert M; Komwilaisak P
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):335-42. PubMed ID: 15166920
[TBL] [Abstract][Full Text] [Related]
2. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.
Chuansumrit A; Wangruangsatid S; Lektrakul Y; Chua MN; Zeta Capeding MR; Bech OM;
Blood Coagul Fibrinolysis; 2005 Nov; 16(8):549-55. PubMed ID: 16269927
[TBL] [Abstract][Full Text] [Related]
3. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation.
Pihusch M; Bacigalupo A; Szer J; von Depka Prondzinski M; Gaspar-Blaudschun B; Hyveled L; Brenner B;
J Thromb Haemost; 2005 Sep; 3(9):1935-44. PubMed ID: 16102099
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever.
Naing C; Poovorawan Y; Mak JW; Aung K; Kamolratankul P
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):403-7. PubMed ID: 25692521
[TBL] [Abstract][Full Text] [Related]
6. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
Payne EM; Brett SJ; Laffan MA
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):397-402. PubMed ID: 16788316
[TBL] [Abstract][Full Text] [Related]
8. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
[TBL] [Abstract][Full Text] [Related]
9. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
10. Recombinant activated factor VII in patients at high risk of bleeding.
Kubisz P; Stasko J
Hematology; 2004; 9(5-6):317-32. PubMed ID: 15763970
[TBL] [Abstract][Full Text] [Related]
11. Use of recombinant activated factor VII for bleeding in pancreatitis: a case series.
Laffan MA; Tait RC; Blatný J; Espersen K; Grabowska I; Loch-Bakoñska L; Pauzkowska A; Stasiak-Pikula E; Michalska G; Wendon J; Piotrowska K
Pancreas; 2005 Apr; 30(3):279-84. PubMed ID: 15782108
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
Smith OP
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
[TBL] [Abstract][Full Text] [Related]
14. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
15. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome.
Ozelo MC; Svirin P; Larina L
Ann Hematol; 2005 Nov; 84(12):816-22. PubMed ID: 16044315
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.
Poon MC; D'Oiron R; Von Depka M; Khair K; Négrier C; Karafoulidou A; Huth-Kuehne A; Morfini M;
J Thromb Haemost; 2004 Jul; 2(7):1096-103. PubMed ID: 15219192
[TBL] [Abstract][Full Text] [Related]
18. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
19. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
[TBL] [Abstract][Full Text] [Related]
20. Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients.
Chuansumrit A; Teeraratkul S; Wanichkul S; Treepongkaruna S; Sirachainan N; Pakakasama S; Nuntnarumit P; Hongeng S;
Blood Coagul Fibrinolysis; 2010 Jun; 21(4):354-62. PubMed ID: 20449890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
